Astrazeneca PLC 6-K, filed Feb 26, 2025
Astrazeneca PLC (AZN)
6-K
2025-02-26
For: 2025-02-26
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on February 26, 2025.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F
__
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is
also
thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of
1934.
Yes
__ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Camizestrant improved PFS in 1L HR+ breast cancer
This announcement contains inside information
26
February 2025
Camizestrant demonstrated highly statistically significant and
clinically meaningful improvement in progression-free survival in
1st-line advanced HR-positive breast cancer with an
emergent ESR1 tumour mutation in SERENA-6
Phase III trial
First and only next-generation oral SERD and complete ER antagonist
to demonstrate 1st-line benefit in combination with widely approved
CDK4/6 inhibitors
Positive
high-level results from a planned interim analysis of the SERENA-6
Phase III trial showed that AstraZeneca's
camizestrant in
combination with a cyclin-dependent kinase
(CDK) 4/6 inhibitor
(palbociclib, ribociclib or abemaciclib) demonstrated a highly
statistically significant and clinically meaningful improvement in
the primary endpoint of progression-free survival (PFS). The trial
evaluated switching to the camizestrant
combination versus continuing standard-of-care
treatment with an aromatase inhibitor (AI) (anastrozole or
letrozole) in combination with a CDK4/6 inhibitor in the 1st-line
treatment of patients with hormone receptor
(HR)-positive,
HER2-negative advanced breast cancer whose tumours have an
emergent ESR1 mutation.
The key
secondary endpoints of time to second disease progression (PFS2)
and overall survival (OS) were immature at the time of this interim
analysis. However, the camizestrant combination demonstrated a
trend toward improvement in PFS2. The trial will continue as
planned to further assess key secondary endpoints.
SERENA-6
is the first global, double-blind, registrational Phase III trial
to use a circulating tumour DNA (ctDNA)-guided approach to detect
the emergence of endocrine resistance and inform a switch in
therapy before disease progression. The novel trial design used
ctDNA monitoring at the time of routine tumour scan visits to
identify patients for early signs of endocrine resistance and the
emergence of ESR1 mutations. Following
detection of an ESR1 mutation without disease
progression, the endocrine therapy of patients was switched to
camizestrant from ongoing treatment with an AI, while continuing
combination with the same CDK4/6 inhibitor.
François-Clément Bidard, MD, PhD, Professor
of Medical Oncology
at Institut Curie & UVSQ/Université
Paris-Saclay, France, and co-principal investigator for the
trial, said: "Patients have an urgent need for new treatments that
delay disease progression on 1st-line endocrine-based therapies.
The results from SERENA-6 show that switching from an aromatase
inhibitor to camizestrant in combination
with any of the three CDK4/6
inhibitors after emergence of
an ESR1 mutation
delays progression of disease and extends the benefit of 1st-line
treatment, representing an important step forward for patients, and
a potential shift in clinical practice."
Susan
Galbraith, Executive Vice President, Oncology Haematology R&D,
AstraZeneca, said: "These
impressive results demonstrate the versatility of camizestrant in
combination with all the widely approved CDK4/6 inhibitors to
provide a well-tolerated new potential treatment option in the
first-line setting for the one in three patients with HR-positive,
HER2-negative advanced breast cancer whose tumours
develop ESR1 mutations
during treatment with an aromatase inhibitor in combination with a
CDK4/6 inhibitor. This critical read-out moves us one step closer
to realising the potential of camizestrant to become a new
standard-of-care as we look to shift the treatment paradigm and
establish this new endocrine therapy backbone in HR-positive breast
cancer."
The safety profile of camizestrant in combination with
palbociclib, ribociclib or abemaciclib in SERENA-6 was consistent
with the known safety profile of each medicine. No new safety
concerns were identified and discontinuations were very low and
similar in both arms.
Globally,
approximately 200,000 patients with HR-positive breast cancer are
treated with a medicine in the 1st-line setting; most frequently
with endocrine therapies that target estrogen receptor
(ER)-driven disease, which are often paired with CDK4/6
inhibitors.1-3 However,
resistance to CDK4/6 inhibitors and current endocrine therapies
develops in many patients with advanced disease.3
Mutations
in the ESR1 gene
are a key driver of endocrine resistance and are widely tested for
in clinical practice.4,5 These
mutations develop during treatment of the disease, becoming more
prevalent as the disease progresses and are associated with poor
outcomes.4,5 Approximately
30% of patients with endocrine sensitive HR-positive disease
develop ESR1 mutations during 1st-line
treatment without disease progression.1
Data will be presented at a forthcoming medical meeting and shared
with global regulatory authorities.
Notes
HR-positive breast cancer
Breast
cancer is the second most common cancer and one of the leading
causes of cancer-related deaths worldwide.6 More than two
million patients were diagnosed with breast cancer in 2022, with
more than 665,000 deaths globally.6 While survival
rates are high for those diagnosed with early breast cancer, only
about 30% of patients diagnosed with or who progress to metastatic
disease are expected to live five years following
diagnosis.7
HR-positive
breast cancer, characterised by the expression of estrogen or
progesterone receptors, or both, is the most common subtype of
breast cancer with 70% of tumours considered HR-positive and
HER2-negative.7 ERs often drive
the growth of HR-positive breast cancer cells.8
Once
resistance to the treatment of HR-positive breast cancer with
CDK4/6 inhibitors and current endocrine therapies occurs, treatment
options are limited and survival rates are low with 35% of patients
anticipated to live beyond five years after diagnosis.3,7,9 The
optimisation of endocrine therapy and overcoming resistance to
enable patients to continue benefiting from these treatments, as
well as identifying new therapies for those who are less likely to
benefit, are active areas of focus for breast cancer
research.
SERENA-6
SERENA-6
is a Phase III, double-blind, randomised trial evaluating the
efficacy and safety of camizestrant in combination with a CDK4/6
inhibitor (palbociclib, ribociclib or abemaciclib ) versus
treatment with an AI (anastrozole or letrozole) in combination with
a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in
patients with HR-positive, HER2-negative advanced breast cancer
(patients with either locally advanced disease, or metastatic
disease) whose tumours have an emergent ESR1 mutation.
The
global trial enrolled 315 adult patients with histologically
confirmed HR-positive, HER2-negative advanced breast cancer,
undergoing treatment with an AI in combination with a CDK4/6
inhibitor as 1st-line treatment. The primary endpoint of the
SERENA-6 trial is PFS as assessed by investigator, with secondary
endpoints including OS, and PFS2 by investigator
assessment.
Camizestrant
Camizestrant
is an investigational, potent, next-generation oral selective
estrogen receptor degrader (SERD) and complete ER antagonist that
is currently in Phase III trials for the treatment of HR-positive
breast cancer.
AstraZeneca's
broad, robust and innovative clinical development programme,
including the SERENA-6, SERENA-4, CAMBRIA-1 and CAMBRIA-2 trials,
is evaluating the safety and efficacy of camizestrant when used as
a monotherapy or in combination with other agents to address a
number of areas of unmet need in this specific type of breast
cancer.
Camizestrant
has demonstrated anti-cancer activity across a range of preclinical
models, including those with ER-activating mutations. In the
SERENA-2 Phase II trial, camizestrant demonstrated PFS benefit
versus Faslodex (fulvestrant)
irrespective of ESR1 mutation status or prior
treatment with CDK4/6 inhibitors in patients with ER-positive
locally advanced or metastatic breast cancer, previously treated
with endocrine therapy. The SERENA-1 Phase I trial demonstrated
that camizestrant is well tolerated and has a promising anti-tumour
profile when administered alone or in combination with palbociclib,
ribociclib and abemaciclib; three widely used CDK4/6 inhibitors.
Combinations with other agents are ongoing in
SERENA-1.
AstraZeneca in breast cancer
Driven
by a growing understanding of breast cancer biology, AstraZeneca is
challenging, and redefining, the current clinical paradigm for how
breast cancer is classified and treated to deliver even more
effective treatments to patients in need - with the bold ambition
to one day eliminate breast cancer as a cause of
death.
AstraZeneca
has a comprehensive portfolio of approved and promising compounds
in development that leverage different mechanisms of action to
address the biologically diverse breast cancer tumour
environment.
With Enhertu (trastuzumab
deruxtecan), a HER2-directed ADC, AstraZeneca and Daiichi Sankyo
are aiming to improve outcomes in previously treated HER2-positive,
HER2-low and HER2-ultralow metastatic breast cancer, and are
exploring its potential in earlier lines of treatment and in new
breast cancer settings.
In
HR-positive breast cancer, AstraZeneca continues to improve
outcomes with foundational medicines Faslodex and Zoladex (goserelin) and aims to
reshape the HR-positive space with first-in-class AKT
inhibitor, Truqap (capivasertib), the
TROP-2-directed ADC, Datroway (datopotamab deruxtecan)
and next-generation oral SERD and potential new medicine
camizestrant.
PARP
inhibitor Lynparza (olaparib) is a targeted
treatment option that has been studied in early and metastatic
breast cancer patients with an inherited BRCA mutation. AstraZeneca
with MSD (Merck & Co., Inc. in the US and Canada) continue to
research Lynparza in these settings and to
explore its potential in earlier disease. AstraZeneca is also
exploring the efficacy and safety of saruparib, a potent and
selective inhibitor of PARP1, in combination with camizestrant in
BRCA-mutated, HR-positive, HER2-negative advanced breast
cancer.
To
bring much-needed treatment options to patients with
triple-negative breast cancer, an aggressive form of breast cancer,
AstraZeneca is collaborating with Daiichi Sankyo to evaluate the
potential of Datroway alone and in combination
with immunotherapy Imfinzi (durvalumab).
AstraZeneca in oncology
AstraZeneca
is leading a revolution in oncology with the ambition to provide
cures for cancer in every form, following the science to understand
cancer and all its complexities to discover, develop and deliver
life-changing medicines to patients.
The
Company's focus is on some of the most challenging cancers. It is
through persistent innovation that AstraZeneca has built one of the
most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca
has the vision to redefine cancer care and, one day, eliminate
cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. Cerner CancerMPact database. Accessed February
2025.
2. Lin M, et al. Comparative Overall Survival of
CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy
Alone for Hormone receptor-positive, HER2-negative metastatic
breast cancer. J Cancer. 2020; 10.7150/jca.48944.
3. Lloyd M R, et al. Mechanisms of Resistance to
CDK4/6 Blockade in Advanced Hormone Receptor-positive,
HER2-negative Breast Cancer and Emerging Therapeutic
Opportunities. Clin Cancer
Res. 2022;
28(5):821-30.
4. Brett O, et al. ESR1 mutation as an emerging
clinical biomarker in metastatic hormone
receptor-positive
breast cancer. Breast Cancer
Res. 2021;
23:85.
5. Zundelevich, A, et al. ESR1 mutations are
frequent in newly diagnosed metastatic and loco-regional recurrence
of endocrine-treated breast cancer and carry worse
prognosis. Breast Cancer
Res. 2020; 22:16.
6. Bray
F, et al. Global cancer statistics 2022: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185
countries. CA Cancer J
Clin. 2024 Apr 4. doi: 10.3322/caac.21834.
7. National Cancer Institute. Cancer
Stat facts: Female breast cancer subtypes. Available
at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed
February 2025.
8.
Scabia V, et al. Estrogen receptor positive breast cancers have
patient specific hormone sensitivities and rely on progesterone
receptor. Nat Commun.
2022; 10.1038/s41467-022-30898-0.
9. National Comprehensive Cancer
Network. Clinical Practice Guidelines in Oncology (NCCN
Guidelines). Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed
February 2025.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
26 February 2025
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|